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The aim of this study is to address the outcomes of endoscopic resection compared with surgery in the treatment of
ampullary adenomas. A systematic review and meta-analysis were performed according to Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations. For this purpose, the Medline,
Embase, Cochrane, Literatura Latino-Americana e do Caribe em Cieˆncias da Sau´de (LILACS), Scopus and Cumulative
Index to Nursing and Allied Health Literature (CINAHL) databases were scanned. Studies included patients with
ampullary adenomas and data considering endoscopic treatment compared with surgery. The entire analysis was
based on a fixed-effects model. Five retrospective cohort studies were selected (466 patients). All five studies (466
patients) had complete primary resection data available and showed a difference that favored surgical treatment
(risk difference [RD] = -0.24, 95% confidence interval [CI] = -0.44 to -0.04). Primary success data were identified in all
five studies as well. Analysis showed that the surgical approach outperformed endoscopic treatment for this
outcome (RD = -0.37, 95% CI = -0.50 to -0.24). Recurrence data were found in all studies (466 patients), with a
benefit indicated for surgical treatment (RD = 0.10, 95% CI = -0.01 to 0.19). Three studies (252 patients) presented
complication data, but analysis showed no difference between the approaches for this parameter (RD = -0.15,
95% CI = -0.53 to 0.23). Considering complete primary resection, primary success and recurrence outcomes, the
surgical approach achieves significantly better results. Regarding complication data, this systematic review
concludes that rates are not significantly different.
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Neoplasms of the duodenal papilla are not a common
condition. In studies with autopsy series, there is a reported
prevalence of 0.04% to 0.12% (1,2). As with colon cancer, there
appears to be an adenoma-to-carcinoma progression sequence
in ampullary adenomas and the rate of development of
carcinoma from adenoma has been shown to be 30% (3).
However, the time frame for malignant transformation is not
well established (4). Due to this malignant potential, complete
removal of an adenoma is essential for curative therapy (5).
Pancreaticoduodenectomy (PD) or pylorus-preserving PD
(PpPD) has traditionally been performed to treat tumors of
the ampulla of Vater. However, given the high morbidity and
mortality associated with radical surgery and the adequacy
of local resection for ampullary adenomas, endoscopic
papillectomy (EP) has been established as a safe, effective
and reliable treatment modality for benign tumors of the
ampulla, serving as an alternative to surgery (6). The issue
today is not whether ampullary adenomas can be endosco-
pically resected, but rather, which cases should be resected.
Therefore, accurate preoperative evaluation is necessary,
although this is not always feasible.
The false-negative rate of endoscopic biopsy for cancer has
been reported to be high, ranging from 11.7% to 60% (7) and
the coexistence of carcinoma within adenoma cannot be
excluded by pre-procedural biopsy (8,9). Considering this,
preoperative evaluation must include not only biopsy but
also the size of the tumor, echographic study of the region
and endoscopic findings.
It is agreed that the indication for EP is an adenoma of the
papilla of Vater that is confined to the ampullary region (10).
Therefore, endoscopic snare papillectomy can be performed
on a tumor that has not invaded the muscularis propria ofDOI: 10.6061/clinics/2016(01)06
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the duodenum; it is not indicated when the tumor extends
into the biliary common duct for more than 10 mm. Lesions
that fulfill this criterion can also be treated with surgery,
especially when dysplasia is present in the pre-procedure
biopsy, when ductal dilation without ductal invasion in the
endoscopic ultrasound (EUS) evaluation, or when the tumor
is large in size (more than 4 cm), although the clinical
condition of the patient must be considered.
The management strategies for ampullary adenoma are
expanding; nevertheless, the criteria for its surgical treatment
have not yet been established. Considering the scenario of
difficult preoperative evaluation and the lack of a consensus
and guidelines, it is very hard to find studies that compare
the results of surgical and endoscopic resection in patients
with ampullary adenomas, so this type of comparison has
not yet been reported in systematic reviews.
To address the outcomes of endoscopic resection com-
pared with surgery in the treatment of ampullary adenoma,
we developed and performed this systematic review.
’ MATERIALS AND METHODS
This systematic review of the literature was conducted in
accordance with the Preferred Reporting Items for Systema-
tic Reviews and Meta-analyses (PRISMA) (11) recommenda-
tions and was registered in the PROSPERO (12) international
database (www.crd.york.ac.uk/prospero/) under number
CRD42014015311.
Study identification and selection
The eligibility criteria for the studies included in this
review are shown in Table 1. Studies were identified by
searching electronic databases and scanning the reference
lists of articles. No limits were applied for language. The
search was applied in Medline (considering all years), and in
Embase (considering all years), a shortened strategy was
needed. The Cochrane and Literatura Latino-Americana e do
Caribe em Ciências da Saúde (LILACS) (via BVS) and the
Scopus and Cumulative Index to Nursing and Allied Health
Literature (CINAHL) (via EBSCO) databases were also
reviewed. The last manual search was run on October 1st,
2014. For Medline, automated updates based on the search
strategy were evaluated for new studies monthly until
September 2015. Eligibility assessment and the selection of
screened records were performed independently in an
unblinded standardized manner by two reviewers.
The following search strategy was used for the Medline
database: ‘(Adenoma OR Ampulla of Vater OR Duodenal
Neoplasms OR Common Bile Duct Neoplasms) AND
(Endoscopy OR Duodenoscopy OR Endoscopy, Gastrointestinal)
AND (Pancreaticoduodenectomy OR Surgical Procedures,
Elective OR Laparotomy OR Surgery) AND ((clinical[Title/
Abstract] AND trial[Title/Abstract]) OR clinical trials as
topic[MeSH Terms] OR clinical trial[Publication Type]
OR random*[Title/Abstract] OR random allocation[MeSH
Terms] OR therapeutic use[MeSH Subheading]) OR Com-
parative study OR Comparative studies OR Random*) NOT
(Colonoscopy OR Colonic Neoplasms OR Colorectal Neo-
plasms OR Rectal Neoplasms OR Anal Canal OR pituitary
surgery OR Pituitary Neoplasms OR Lung Neoplasms OR
Pleural Neoplasms OR Mesothelioma OR Skull Base OR
Neurosurgical Procedures OR Parathyroidectomy OR Neck
OR Hyperparathyroidism OR Adrenalectomy OR Adrenal
Gland Diseases)’. As part of the process, the Medline search
strategy was peer reviewed.
The Embase search was as follows: ‘(Adenoma OR
Ampulla of Vater OR Duodenal Neoplasms OR Common
Bile Duct Neoplasms) AND (Endoscopy OR Duodenoscopy
OR Endoscopy, Gastrointestinal) AND (Pancreaticoduode-
nectomy OR Surgical Procedures, Elective OR Laparotomy
OR Surgery) NOT (Colonoscopy OR Colonic Neoplasms OR
Colorectal Neoplasms OR Rectal Neoplasms OR Anal Canal
OR pituitary surgery OR Pituitary Neoplasms OR Lung
Neoplasms OR Pleural Neoplasms OR Mesothelioma OR
Skull Base OR Neurosurgical Procedures OR Parathyroidect-
omy OR Neck OR Hyperparathyroidism OR Adrenalectomy
OR Adrenal Gland Diseases)’.
For the Cochrane, LILACS, Scopus and CINAHL data-
bases, the search was ‘Duodenal Neoplasms AND Endo-
scopy AND Surgical Procedures’.
Data collection process
The method of data extraction from each included study
consisted of filling out an information sheet after the paper
was read. A Scottish Intercollegiate Guidelines Network
(SIGN) (13)-based checklist was gathered from the internet
site www.sign.ac.uk. Relevant data were then extracted from
each included study using a standardized extraction form.
One review author extracted the data mentioned below from
the included studies and a second author checked the
extracted data. Disagreements were resolved by discussion
between the two review authors.
The following information was extracted from each
included trial: the characteristics of the trial participants,
the trial’s inclusion and exclusion criteria, the type of inter-
vention and outcome data. The chosen outcomes were
defined as shown in Table 2.
To ascertain the validity of eligible studies, the two
reviewers, working independently and with adequate relia-
bility, measured the risk of bias; these data were assessed
using the Newcastle-Ottawa Quality Assessment Scale (14)
Table 1 - Eligibility criteria.
Types of studies Comparative studies (clinical trials and/or
observational studies)
Types of participants Patients who had been diagnosed with
ampullary adenoma
Types of interventions Trials comparing outcomes between two
groups (endoscopic treatment and
surgery). There were no restrictions
regarding the different modalities of
treatment in each group
Types of outcomes or
outcome measures
The main outcome measures were complete
resection, primary success, recurrence and
complications related to the procedures
Table 2 - Outcomes.
Complete primary
resection
The first procedure was able to completely
extract the neoplasia, with free margins
Primary success The initial procedure was sufficient to achieve
complete cure of the adenoma within the
follow-up period
Recurrence After primary complete resection, the patient
appeared to undergo a relapse of the adenoma,
which was detected during the follow-up
Complication Complications related to the procedure were
present
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for cohort studies and the SIGN checklist (13). The critical
evaluation of the included trials was expected to reveal a
scoreX6, with a total of 9 being the highest possible score on
the Newcastle-Ottawa Scale. The levels of evidence accord-
ing to the Oxford Centre for Evidence-Based Medicine (15)
were also obtained.
Statistical analysis
The risk differences (RDs) for the complete primary
resection, primary success, complication and recurrence rates
after treatment of ampullary adenoma were the outcomes
measured. In addition, data on absolute risk reduction (ARR)
or increase (ARI) and the number needed to treat (NNT) or
harm (NNH) were analyzed for the main outcomes. For
all statistical calculations, we used a confidence interval (CI)
of 95%.
The analysis was performed using the software Review
Manager (RevMan) 5.3 (16), obtained from the website of the
Cochrane Informatics & Knowledge Management Depart-
ment, by computing RDs for dichotomous variables using
random- and fixed-effects models and generating the
respective forest plots. Data on RDs and 95% CIs for each
outcome were calculated using the Mantel-Haenszel test and
inconsistency (heterogeneity) was quantified and reported
using the Chi-squared (Chi2) test and the Higgins method
and termed I2. The advantages of this last measure are that it
does not inherently depend on the number of studies and
that it is accompanied by an uncertainty interval.
As quantification of heterogeneity is only one component
of a wider investigation of variability across studies and
considering the clinical implications of the observed degree
of inconsistency across studies, a cut-off value of 50% was
assumed to be adequate for this meta-analysis (17). When the
heterogeneity (I2) was greater than 50%, we compared the
findings between the random- and fixed-effects models, and
if no difference was found in the final results, true hetero-
geneity was presumed, i.e., significant publication bias was
excluded.
Publication bias is concerned with what is likely to be
published relative to what is available to be published. One
problematic and much-discussed bias is the tendency of
researchers and editors to handle the reporting of experi-
mental results that are positive (i.e., showing a significant
finding) differently from those results that are negative (i.e.,
supporting the null hypothesis) or inconclusive, leading to a
misleading bias in the overall published literature (18).
’ RESULTS
Study identification and selection
Throughout the search strategy, three thousand, three
hundred and sixty-four (3364) studies were screened and
eligible articles were selected after the title and abstract were
read. Three thousand, three hundred and fifty-three (3353)
articles were excluded due to not being related to the subject
or not being comparative studies. The full text of the eleven
remaining studies was assessed for eligibility. Six articles
were excluded: Ridtitid et al. (19) and Patel et al. (20) because
only the abstract was available, so it was impossible to
extract data; Ismail et al. (21) because a series of cases of
papillectomy with no primary surgical treatment;
Ito et al. (22) because adenoma patients were not included
in the surgical group; Lepistö et al. (23) because of the
impossibility of separating ampullary and non-ampullary
lesions; and Okano et al. (24) because a diagnostic study
without therapeutic endpoints was conducted. The remain-
ing five studies were included in qualitative and quantitative
syntheses. An adapted PRISMA flow diagram illustrates the
study selection process (Figure 1).
Study characteristics
Methods. The five articles selected for review were
retrospective studies. All of them were published in English.
Participants. The included records involved 466 patients.
The main inclusion criterion was the presence of an ampullary
adenoma that was managed with endoscopic or surgical
treatment. All follow-up periods were considered.
Intervention. The mainly endoscopic approach analyzed
was endoscopic snare papillectomy (ESP). Complementary
techniques such as hot biopsy (HB) and argon-plasma coagula-
tion (APC) were also included.
Comparison. The surgical approaches were PD and
transduodenal resection (TDR), depending on the clinical
condition of the patient. Both these approaches were together
compared with the endoscopic approach.
Outcomes. The assessed outcomes were the complete pri-
mary resection, primary success, recurrence and complication
rates.
A summary of the characteristics of the included studies is
shown in Table 3.
Methodological quality and risk of bias
The risk of bias was assessed using a standard approach
with defined criteria, as previously mentioned. Data from
each selected study and the levels of evidence are shown in a
tabular format (Table 4). All five included studies obtained a
score of 8 according to the Newcastle-Ottawa Quality Assess-
ment Scale (14) for cohort studies.
Other parameters were used to increase confidence in the
strength of association between exposure and outcome by
identifying aspects of good study design. According to the
SIGN checklist (13), all studies were considered acceptable,
i.e., having certain flaws and an associated risk of bias (the
possibility of a change in the conclusions in light of further
studies). The SIGN classification considers three category
levels: 0 (low quality), + (acceptable) and ++ (high qua-
lity). All of the included studies were classified as having a
level of evidence of 2B (Oxford Centre for Evidence-Based
Medicine (15)).
Analysis of outcomes
The data on effect estimates and CIs for each study are
shown graphically. The numerical group-specific summary
information, effect size, CI and percentage weight are also
shown in the following tables (forest plots).
Complete primary resection
All five studies were available for the complete primary
resection analysis. As shown in Figure 2, high heterogeneity
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was found (Chi2=63.83 and I2=94%), but no change in the
effect was found in the comparison between the random-
and fixed-effects models, indicating true heterogeneity
between the studies. Data analysis showed a difference that
favored surgical treatment (RD=-0.24, 95% CI=-0.44 to -0.04).
The NNH calculated was 5, indicating that for every five
patients who are endoscopically treated, one would be harmed
in not undergoing complete resection (and would have
benefited from surgical treatment with complete resection).
Primary success
Primary success data were identified in all five studies. The
heterogeneity detected was higher than desirable (Chi2=13.86
and I2=71%) within this comparison (Figure 3), but the
comparison of the effects models did not show a difference,
implying true heterogeneity. Analysis of the 466 patients
showed that the surgical approach was more successful than
endoscopic treatment in terms of primary success (RD=-0.37,
95% CI=-0.50 to -0.24).
Figure 1 - Search strategy and study selection flowchart.
Table 3 - Summary of the included studies.
Study Study design Number of patients Endoscopic
approach (EA)
Surgical approach (SA) Follow-up (median)
EA / SA
Outcomes
Onkendi EO et al., 2014 (25) RC 180 ESP; APC PD; TDR 48.4 mo (SDNA) CPR; PS; R; C;
Kim HN et al., 2013 (26) RC 91 ESP; HB DNA 26.6 mo / 26.6 mo CPR; PS; R; C;
Irani S et al., 2009 (27) RC 123 ESP; APC PD 40 mo / DNA PS; C;
Kim JH et al., 2009 (28) RC 33 ESP PD; TDR 20 mo / 60.6 mo CPR; PS; R;
Yoon SM et al., 2007 (29) RC 39 ESP; APC PD 29.6 mo / 57.1 mo CPR; PS; R; C;
RC: Retrospective Cohort; CPR: Complete Primary Resection; PS: Primary Success; R: Recurrence; C: Complications; ESP: Endoscopic Snare Papillectomy;
HB: Hot Biopsy; APC: Argon-Plasma Coagulation; PD: Pancreaticoduodenectomy; TDR: Transduodenal Resection; mo: Months; DNA: Data Not Available;
SDNA: Separate Data Not Available.
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The pooled NNH was 3, showing that for every three
patients who are endoscopically treated, one would not be
cured by the first procedure and would need complementary
treatment (and would have benefited from surgical treat-
ment, with no need for additional resection).
Recurrence
All five studies had recurrence data available for analysis.
Although high heterogeneity was detected (Chi2=13.23 and
I2=70%), as shown in Figure 4, it was considered to be true
heterogeneity, as no difference in the result was found with
the fixed-effects model. The data analysis showed that in the
466 patients, surgical treatment led to less recurrence in
comparison with endoscopic treatment for ampullary ade-
nomas (RD=0.10, 95% CI=0.01 to 0.19). The NNH calculated
was 10, meaning that for every 10 patients who is treated
with endoscopy, one would experience recurrence of the
lesion in the follow-up period (this would not happen if
surgical treatment was used).
Complications
Complication data were identified for 254 patients (three
studies). There was high heterogeneity in the sensitivity
analysis (Chi2=44.00 and I2=95%). Random-effects model
analyses showed no difference between surgical and endo-
scopic treatment (RD=-0.15, 95% CI=-0.53 to 0.23) (Figure 5),
differing from what was found with the fixed-effects model,
which showed fewer complications with the endoscopic
approach (RD=-0.28, 95% CI=-0.39 to -0.18) (Figure 6). This
finding, along with the high heterogeneity, suggests that
publication bias may have been present.
’ DISCUSSION
Ampullary adenomas are well known as premalignant
lesions. An adenoma-to-carcinoma sequence similar to that
in colonic cancer is well described (30) and because of that,
resection is mandatory.
Endoscopic treatment for ampullary adenomas is well
established by more than 30 years of experience all over the
world, with the first description in 1983 by Suzuki et al. (31).
ESP is a minimally invasive procedure with high success and
low recurrence rates, although it has a significant risk of
complications.
The advantage of the surgical approach via PD is that it is
a ‘gold standard’ procedure, with a historic legacy that
extends from the late 19th century, and specifically 1889,
when Codivilla reported the first PD. Over the following
years, this approach’s ominous prohibitive mortality was
reduced and currently, its mortality rate is less than 2% in
reference centers (32). Nevertheless, PD continues to be a
very challenging and risky procedure and certain patients do
not have adequate clinical conditions for this intervention.
For example, in a study by Yoon et al., several patients were
not managed surgically because of poor preoperative con-
ditions, including advanced age and significant comorbid-
ities (29).
The critical point in the management of these patients is
the indication for endoscopic treatment. Although it is well
understood that EP should be performed only when the
adenoma is confined to the ampullary region, the specific
indication criteria are not yet fully established (10,33).
Summarizing all of the criteria utilized in the five studies
included in the present review, we have derived the































Onkendi EO et al.,
2014 (25)
2 1 1 1 1 2 8 – 2B -
acceptable (+)
Kim HN et al.,
2013 (26)
2 1 1 1 1 2 8 – 2B -
acceptable (+)
Irani S et al.,
2009 (27)
2 1 1 1 1 2 8 – 2B -
acceptable (+)
Kim JH et al.,
2009 (28)
2 1 1 1 1 2 8 – 2B -
acceptable (+)
Yoon SM et al.,
2007 (29)
2 1 1 1 1 2 8 – 2B -
acceptable (+)
^ Oxford Centre for Evidence-Based Medicine and Scottish Intercollegiate Guidelines Network ratings.
Figure 2 - Complete primary resection data after endoscopic or surgical treatment of ampullary adenomas.
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following contraindications for endoscopic treatment: endo-
scopic impression of malignancy (friability, ulceration, lateral
spread, obvious duodenal infiltration), size44 to 4.5 cm and
intraductal extension of more than 1 cm on endoscopic
retrograde cholangiopancreatography (ERCP) or EUS.
Another very important point in the management of these
lesions is the reliability of the preoperative evaluation in terms
of distinguishing between benign and malignant ampullary
tumors. Certain authors have suggested that malignancy
might be missed in up to 30% of tumors in the major duodenal
papilla when forceps biopsy specimens are obtained (34). As
the coexistence of carcinoma within adenoma cannot be
completely excluded by pre-procedural biopsy, the use of ESP
as a diagnostic tool (a ‘total biopsy’) should be considered and
would be useful as a screening method for identifying those
patients who will need surgical treatment.
As shown in Table 3, the follow-up period was satisfactory
for both interventions in all selected studies, with means of
32.9 months for the endoscopic approach and 48.2 months for
the surgical approach. It is well established that a follow-up
period of 6 months would be sufficient to define the absence
of recurrence after treatment of ampullary adenomas (33,35).
The data analysis for primary success, with 466 patients,
showed a significant difference that favored surgical treatment
(RD=-0.37, 95% CI=-0.50 to -0.24 and po0.0001). This result, with
an NNH of 3, shows that for every three patients who are treated
with endoscopy, one would be harmed, without achievement of
a cure, if this is the first procedure (whereas the patient would
benefit if treated surgically). The primary failings found in the
follow-up period were when the patient experienced recurrence
or residual disease. Residual disease was measured indirectly
based on the complete primary resection rate. Data analysis for
this outcome for the 466 patients in our review showed a
significant difference that favored surgical treatment (RD=-0.24,
95% CI=-0.44 to -0.04 and p=0.02). This finding was expected, as
the majority of the surgical procedures performed were PD,
which extracts the entire duodenum. The recurrence data, with
all 466 patients included, also showed better results for the
surgical approach (RD=0.10, 95% CI=0.01 to 0.19 and p=0.03).
Although surgical treatment showed less recurrence and residual
disease, it is also important to highlight that when found after
ESP, both of these findings are usually benign and most of them
can be treated endoscopically (27,29,33,35).
As previously noted, ESP is considered as a procedure
with a high risk of complications. In our analysis, only three
studies provided complication data for both the surgical and
the endoscopic approaches (Yoon et al., 2007; Kim et al.,
2009; and Onkendi et al., 2014), with no significant difference
between the two groups when using the random-effects
model. However, using the fixed-effects model, the results
showed a benefit for endoscopic treatment (RD=-0.28, 95%
CI=-0.39 to -0.18 and po0.00001). This finding, along with
the high heterogeneity, did not permit the exclusion of
publication bias in the studies by Yoon et al. and Kim et al.,
which showed a very low complication rate for both the
endoscopic and the surgical approaches. As the only cases of
complications reported in these two studies were related to
mortality, it is reasonable to assume that minor complication
data were not available or were even omitted. The other two
studies (Kim HN et al., 2013 and Irani et al., 2009), which did
Figure 3 - Primary success data after endoscopic or surgical treatment of ampullary adenomas.
Figure 4 - Recurrence data after endoscopic or surgical treatment of ampullary adenomas.
Figure 5 - Complication data after endoscopic or surgical treatment of ampullary adenomas (random-effects model).
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not show complication data for the surgical approach,
reported ESP complication rates of 28% and 20.5%, respec-
tively, which are compatible with other findings in the
literature, with complication rates for the endoscopic app-
roach varying from 8 to 35% (33,36).
Undoubtedly, EP can be an effective primary therapy for
ampullary adenoma and it is currently already an interesting
option in many cases of ampullary adenoma. However,
surgical treatment is very well established and there are no
prospects of major changes in the coming years. In contrast,
future evolution in the endoscopic area are a reality, and new
technologies and standardization of techniques for endo-
scopic removal of ampullary adenoma may ensure more
complete removal and minimal complications related to the
endoscopic procedure, expanding the indications for EP.
As no guidelines are fully accepted regarding the treatment
of ampullary adenomas, the management of this condition
relies on the decision of the attending physician or medical
staff and depends on the complex interaction of different
factors, such as the patient’s clinical condition and age, tumor
characteristics, physician expertise (surgeons, pathologists and
endoscopists) and hospital infrastructure. Regardless of the
chosen technique, the patient should be treated in reference
centers by trained and experienced professionals to ensure
similar results as shown in this review.
The lack of studies comparing surgical and endoscopic
treatment for ampullary adenoma is a fact. In the present
study, the literature search represented a limitation, providing
a low number of studies for analysis, with no randomized
trials. The main reasons for this limitation are the absence of
guidelines for the management of this disease and difficulty in
defining the adequate indications for either surgery or EP.
The comparison between the findings with the random-
and fixed-effects models showed a difference only in the
complication outcome, meaning that publication bias could
not be excluded. The presence of high heterogeneity and the
lack of a difference in the comparison of the two effects
models for the other outcomes indicate that true hetero-
geneity existed between the selected studies. A certain
degree of heterogeneity is inevitable in a medical meta-
analysis, but the impact of between-study heterogeneity may
undermine the quality and legitimacy of the results obtained.
Considering complete primary resection, primary success and
recurrence outcomes when comparing the endoscopic approach
with the surgical approach for the treatment of ampullary
adenomas, the surgical approach achieves significantly better
results. Regarding complication data, this systematic review
concludes that rates are not significantly different.
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